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1. Introduction 
Peritoneal dialysis (PD) is a life-supporting renal replacement therapy used by 10-15% of 
patients with end-stage renal failure worldwide. The success of long-term PD depends entirely 
on the longevity and integrity of the peritoneal membrane. The peritoneum is covered by a 
mesothelial monolayer beneath which is a basement membrane and submesothelial layer that 
contains collagen, fibroblasts, adipose tissue, blood vessels and lymphatics. During PD, 
peritoneal cells are repeatedly exposed to a non-physiological hypertonic environment with 
high glucose content and low pH. Mesothelial cells (MCs) play an important role in regulating 
the inflammatory response in the peritoneal cavity: they produce pro-inflammatory cytokines 
and chemoattractants. By secreting these chemokines or cytokines, MCs contribute to the 
recruitment of leukocytes following the expression of adhesion molecules. Chronic changes in 
the peritoneum with fibrosis develop after years of peritoneal dialysis. The most marked 
changes are in cases of severe and recurrent peritonitis. Others have made similar observations 
that long-term exposure to peritoneal dialysis solutions appears to increase fibrosis and the 
probability of ultrafiltration failure. Encapsulating peritoneal sclerosis represents the most 
severe and fatal complication of membrane failure.  
Conventional peritoneal dialysis fluids (PDFs) make use of the osmotic gradient generated 
by glucose. Years of exposure to PDFs compounded with peritonitis result in the formation 
of an avascular layer of interstitial matrix and plasma proteins in the sub-mesothelial 
compact zone and an epithelial-to-mesenchymal transition (EMT) of mesothelial cells [1]. 
The fibrotic process in the peritoneal membrane is developed following acute and chronic 
release of inflammatory mediators related to PD. Independent extrinsic and intrinsic events 
(Table 1) contribute to chronic inflammation in patients on PD leading to complications 
including peritoneal membrane ultrafiltration failure, fluid overload, protein energy 
wasting and even atherosclerosis.  
2. Extrinsic factors   
2.1 Uremia 
It has been shown that the peritoneum of uremic and current hemodialysis patients who 
have never exposed to PD is abnormal as well; this finding implies that uremia induces 
inflammation in the peritoneum [2]. There is a marked increase in vasculopathy below the 
compact zone. 
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Extrinsic Factors   
 Uremia 
 PDFs 
 Infections – especially peritonitis 
Intrinsic Factors  
 Mesothelium 
 Sub-mesothelial compact zone  
 Sub-mesothelial blood vessels 
 Epithelial-to-mesenchymal transition (EMT) 
 Receptors for GDPs and AGE 
 Macrophages 
 Peritoneal adipocytes 
Table 1. Events promoting chronic inflammation in PD 
2.2 Peritoneal Dialysis Fluids (PDFs) 
D-glucose is a reactive compound that exerts effect on the mesothelial cells directly by up-
regulating the synthesis of transforming growth factor- (TGF-) and connective tissue growth 
factor by MCs or through its degradation pathway into glucose degradation products (GDPs) 
and formation of advanced glycation end-products (AGEs). Exposure to GDPs leads to 
enhanced cytotoxic damage and pro-inflammatory response in MCs stimulating the 
production of vascular endothelial growth factor (VEGF) that enhances vascular permeability 
and angiogenesis. GDPs also down-regulate the expression of intercellular tight junction 
proteins like ZO-1, occludine and claudin-1 in MCs, again via VEGF [3].  
Factors such as the buffer, glucose or GDPs formed during heat sterilization, are critical in 
determining the biocompatibility of different PDFs. Mesothelial cell repair 
(remesothelialization) after exposure to GDPs is impaired, independent of D-glucose 
concentration. After exposure of mesenchymal cells to PDFs, the expression of cytokeratin 
18 and E-cadherin is reduced while the expression of -SMA and vimentin as a sign of EMT 
is increased [4]. Expression of intercellular tight junction proteins is down-regulated after 
incubation with PDFs.  
2.3 Infection 
Bacterial peritonitis is associated with a sharp increase in total cell and neutrophil counts 
(400-fold) in PDFs up to 2-3 weeks after peritonitis despite clinical remission [5]. There was a 
progressive increase in the percentage of mesothelial cells or dead cells in the total cell 
population in PDFs. Dialysate levels of interleukin-1┚ (IL-1┚), interleukin-6 (IL-6), tumor 
necrosis factor-Fand TGF- increased markedly on day 1 before their levels 
decreased gradually [5,6]. This active release of pro-inflammatory cytokines and sclerogenic 
growth factors may continue some time despite clinical remission of peritonitis. The 
peritoneal cytokine networks after peritonitis may potentially affect the physiological 
properties of the peritoneal membrane [5].  
3. Intrinsic factors   
3.1 Mesothelium 
Peritoneal mesothelial cells are biologically active and play distinctive biological roles other 
than local host defense [3]. The MCs are sensitive to the effect of pH despite the 
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conventional PDFs are usually buffered from pH of 5.2–7.4 in 15–30 min in clinical studies 
while TGF- production by MCs is less with bicarbonate-buffered PDF. Glucose in the PDF 
can bring about major changes in the environment of the mesothelial cells as well as that of 
the cells underlying the mesothelium and the production of various cytokines are increased 
as a result of this exposure (Table 2). The peritoneal membrane also synthesizes 
prosteoglycans, expresses AGE receptors and produces aquaporins [3,7]. It is noteworthy 
that glucose may exert little effect on the synthesis of specific mediators, such as VEGF yet 
its synthesis is greatly enhanced by GDPs or AGE. Serial peritoneal biopsy study shows 
denudation of the mesothelial monolayer as early as six months after maintenance PD. 
 
 Synthesis of chemokines: MCP-1, RANTES, Interferon--
inducible protein-10 
 Synthesis of fibrogenic cytokines – TGF-, bFGF 
 Synthesis of prosteoglycans 
 Induction of angiogenesis – VEGF 
 Expression of AGE receptors 
Table 2. Biological role of peritoneal mesothelium 
3.2 Sub-mesothelial compact zone  
After years of continuous peritoneal dialysis, a good percentage of patients would have 
marked increase in the thickness of the submesothelial compact zone. The layer resembles 
scar tissue with a relatively amorphous, avascular appearance. Animal studies reveal that a 
spotty inflammation is detected at different places of the peritoneum in the first few weeks 
of exposure to PDF. With time, these areas of inflammation and sclerosis gradually coalesce 
and become more uniform to cover much of the peritoneum that is in contact with the PDF. 
As the fibrosis becomes more uniform, the patient will gradually lose ultrafiltration.  
3.3 Sub-mesothelial blood vessels 
In parallel with fibrosis, the peritoneum shows a progressive increase in capillary number 
(angiogenesis) and vasculopathy, which are involved in both the elevation of small solute 
transport across the peritoneal membrane and ultrafiltration failure. GDPs stimulate VEGF 
production by MCs [8]. Local production of VEGF during PD appears to play a central role 
in the processes leading to peritoneal neo-angiogenesis and functional decline. The changes 
in the structure of the peritoneal function over time on PD as found in functional tests has 
been confirmed in biopsy studies performed on patients [2]. These show both neo-
angiogenesis and fibrosis as the underlying morphological changes contributing to these 
phenomena. As mentioned previously, uptake of the glucose by sub-mesothelial blood 
vessels will be quite rapid following increased permeability due to abnormal angiogenic 
vessels and the increased surface area of the microvasculature. This results in dissipation of 
the osmotic driving force through increased area and solute transport. In addition, 
disruption of intercellular tight junction in MCs may occur following down-regulation of 
ZO-1 expression in which VEGF plays an important role [3,8].  
3.4 Epithelial-to-mesenchymal transition (EMT) 
Chronic exposure of the mesothelium to sterile PDFs may result in an EMT. Local 
inflammation and oxidative stress, which results from the continuous peritoneal injury, 
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accelerate the EMT of peritoneal mesothelial cells resulting in peritoneal fibrosis and 
ultrafiltration failure. EMT is a process by which the MCs undergo a progressive loss of 
epithelial phenotype and acquire fibroblast-like characteristics, which allows these cells to 
invade the mesothelial stroma contributing to angiogenesis, fibrosis and ultrafiltration 
failure. Yanez-Mo et al. [9] recovered and cultured human MCs from the spent dialysate of 
54 stable patients. Eighty-five percent of these patients had no previous peritonitis. Omental 
fibroblasts were separated from three of omental MCs samples from 39 CAPD patients. 
There was a transition from an epithelial type of mesothelial cell to a fibroblast-like cell with 
loss of normal markers of the mesothelium and phenotypic changes following progressive 
and continuous exposure to PDFs. For patients who were exposed to dialysate for more than 
12 months, their mesothelial cells changed from 75% cobblestone phenotype to less than 
30% with the remainder being fibroblast-like. In some patients they observed that in less 
than 9 months there was loss of cytokeratin in the mesothelial cell layer. These findings 
suggest chronic exposure to the peritoneum to the current glucose-based PDFs could lead to 
morphologic and phenotypic changes in the mesothelium with 24 months. 
Transforming growth factor-, more specifically TGF-1, is one of the main mediators of the 
PD solutions’ profibrotic effects through the Smads 2 and 3 pathways. These effects include 
fibroblast activation, collagen deposition, inhibition of fibrinolysis, maintenance of fibrosis 
and neoangiogenesis [3]. Acting through the Smad pathway, TGF- induces -catenin 
formation which in conjunction with Activator Protein-1 activates matrix metalloproteinase-
9 expression facilitating the invasion of the extracellular matrix [10]. Interestingly, 
angiotensin II inhibitors (which are TGF- activity suppressors) have recently been shown to 
reduce peritoneal fibrosis and neoangiogenesis, as well as to prevent the increase of small 
solute transport in long-term PD patients [11]. Non-viral microbubble-delivery of Smad7 
transgene markedly abolishes the peritoneal fibrosis induced by glucose-containing PDF 
[12]. Neutrophil gelatinase-associated lipocalin (NGAL) is specifically induced in human 
peritoneal MCs by interleukin-1. Leung et al. [13] demonstrated that incubation of human 
peritoneal MCs with recombinant NGAL reversed the TGF--induced up-regulation of 
Snail and vimentin but rescued the down-regulation of E-cadherin. Their in vitro data 
suggest that NGAL may exert a protective effect in modulating the EMT activated following 
peritonitis.  
Lately, Bajo et al. [14] demonstrated a clear association between GDPs present in 
conventional heat-sterilized PDFs and the induction of EMT in the peritoneal membrane. To 
date, no study has investigated the direct correlation between the inflammatory 
environment created as a consequence of recurrent peritonitis episodes and EMT, but many 
of the inflammatory cytokines known to be involved in driving EMT such as IL-1┚, tumor 
necrosis factor- (TNF-┙) and TGF-┚ are present at high concentrations within the 
peritoneal membrane during peritonitis, and more importantly perhaps, the levels of these 
cytokines may remain elevated after the acute inflammatory response has subsided [5]. 
Clearly, the constant exposure of the mesothelial cells to increased levels of inflammatory 
cytokines and growth factors that have a known role to play in driving EMT could 
significantly increase the process of EMT-driven membrane fibrosis. In their study, Bajo et 
al. [14] reported no correlation between number of previous peritonitis episodes and 
mesothelial cell EMT observed in these patients; however, their results do suggest that the 
severity and duration of the peritonitis episode may supersede the protective effects of the 
low-GDP PDFs. 
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3.5 Receptors for GDPs and AGE 
AGEs have been detected immunohistochemically in the peritoneum of PD patients. 
Receptor for advanced glycation end-products (RAGE) is the best characterized signal 
transduction receptor for AGEs. Primarily binding of AGEs to their receptor was regarded 
as a scavenger receptor involved in AGE removal and AGE clearance. However, ligand 
binding to RAGE results in an activation of key signal transduction pathways, such as NF-
B and multiple cellular signaling cascades like activation of MAP kinase. Local interaction 
between RAGE and AGEs/GDPs leads to the development of peritoneal inflammation, neo-
angiogenesis and, finally, fibrosis. Anti-RAGE antibody partially prevents the development 
of submesothelial and interstitial fibrosis and EMT in an animal model of peritoneal fibrosis 
[15]. Aminoguanidine (AG) prevents formation of AGE. Supplementation of AG to PDF 
showed inhibitory effects on peritoneal AGE accumulation, mesothelial denudation, 
submesothelial monocyte infiltration, peritoneal permeability and ultrafiltration, and 
preserved the functional capacity of peritoneal macrophages in the rat.  PDF-induced 
fibrosis was significantly reduced by AG [16]. The use of AG in human is limited by its pH 
and toxicity. 
It is now evident that RAGE is much more than a single receptor for AGEs or a scavenger 
receptor; it has a broad repertoire of ligands. The key pathophysiological step seems to be 
GDP-dependent AGE formation in the uremic milieu, through which an enhanced 
expression of RAGE in the peritoneum could be observed. Recently, other AGE receptors, 
including AGE-R-1 (p 60), AGE-R-2 (p 90) and AGE-R-3 (gallectin-3) are also found to be 
expressed on MCs [17]. Different GDPs exert differential regulation on the regulation and 
expression of these receptors on human peritoneal MCs [17]. However, the functional 
significance of these various forms has not yet been completely delineated.  
3.6 Macrophages 
Resident macrophages increase markedly with bacterial peritonitis and are able to enhance 
the release of peroxide and pro-inflammatory cytokines including interleukin-1┚ and TNF-
. TGF- complementary DNA (cDNA) molecules per macrophage are significantly greater 
than those of macrophages in non-infective PDFs throughout the peritonitis period [5]. 
There was no significant correlation between PDFs levels of TGF- and TGF- cDNA 
molecules per macrophage, suggesting that peritoneal macrophages are not the 
predominant source of TGF- in PDFs.   
4. The “less recognized” inflammatory role of peritoneal adipocytes in PD 
Adipose tissue is abundant in omental or mesenteric peritoneum but less so in parietal, 
intestinal and diaphragmatic peritoneum. Contrary to the prevailing view that adipose 
tissue functions only as an energy storage depot, compelling evidence reveals that 
adipocytes can mediate various physiological processes through secretion of an array of 
mediators and adipokines that include leptin, adiponectin, resistin, TNF-, IL-6, TGF-, 
VEGF and other growth factors [18]. Moreover, adipocytes express receptors for leptin, 
insulin growth factor-1 (IGF-1), TNF-, IL-6, TGF- and may form a network of local 
autocrine, paracrine and endocrine signals [19]. All of these adipokines exert important 
endocrine functions in chronic kidney diseases and may also contribute to systemic 
inflammation in these patients. This is of special significance in patients undergoing PD as 
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the initiation of treatment is often associated with an increase in fat mass that could be 
associated with the genetic effect on energy metabolism in addition to glucose absorption 
from the PDFs [20]. A recent study indicates that an increased fat mass in PD, like in other 
patient groups, may indeed have adverse metabolic consequences with increased systemic 
inflammation and worst survival [21]. Interestingly, there is a difference in the release of 
growth factors between visceral and subcutaneous adipose tissue [22]. The omental adipose 
tissue, most affected by PD, releases IL-6 two to three folds higher than the subcutaneous fat 
tissue [23]. The visceral (truncal) fat mass correlates significantly with circulating IL-6 levels 
but not for non-truncal fat mass [24].  
Ultrastructural study reveals that a portion of omental adipocytes protrude from the 
mesothelial surface, thus may come into direct contact with dialysate [25]. In addition, 
dialysate may also reach the parietal adipose tissue when the mesothelial monolayer is 
damaged. It is therefore logical to postulate that with repeated exposure to PDFs and the 
continuous change in peritoneal physiology during PD, peritoneal adipocytes will 
inevitably be "activated". Although much work has focused on peritoneal mesothelial cells, 
scant attention has been paid to the role of peritoneal adipocytes during PD. 
5. Crosstalk between peritoneal cells and adipocytes 
Leptin is a peptide hormone mainly derived from adipocytes and is cleared principally by 
the kidney. The serum leptin concentration is increased in patients with chronic renal failure 
or undergoing dialysis [26,27] and the serum leptin increases by 189% within a month after 
the initiation of PD treatment [28]. Leptin is also elevated during acute infection, in response 
to proinflammatory cytokines including IL-1 and TNF- [26]. In the kidney, leptin 
stimulates cell proliferation and synthesis of collagen IV and TGF- in glomerular 
endothelial cells. In glomerular mesangial cells, leptin increases the glucose transport, up-
regulates the expression of TGF- type II receptor and the synthesis of collagen I through 
phosphatidylinositol-3-kinase related pathway [26]. Available data suggests that leptin 
triggers a paracrine interaction between glomerular endothelial and mesangial cells through 
the increased synthesis of TGF- in glomerular endothelial cells and upregulated TGF- 
receptor expression in mesangial cells. Whether such paracrine interaction is operating 
between peritoneal adipocytes and MCs remains to be explored. To the best of our 
knowledge, there is only one previous study on the effect of PDF on adipocytes that 
demonstrates increased leptin synthesis in a murine adipocyte cell line (3T3-L1) by glucose-
containing PDFs [29]. It is likely that proinflammatory mediators released by MCs upon 
exposure to PDF could induce functional alteration of adjacent adipocytes. The likely 
candidates are IL-1 and TNF-, TGF-, VEGF and IL-6. Indeed, a recent in vitro study has 
shown that IL-6 modulates leptin production and lipid metabolism in human adipose tissue 
[30]. Using MC and adipocyte cell cultures established in our laboratory, we have shown 
that high glucose content in dialysate fluid is one of the major culprits that causes structural 
and functional abnormalities in peritoneal cells during PD [8,31,32]. Glucose significantly 
increases the protein synthesis of leptin by adipocytes in a dose-dependent manner and up-
regulates the expression of leptin receptor, Ob-Rb, in MCs [31]. The increased leptin 
production by adipocytes and enhanced Ob-Rb expression in MC following exposure to 
glucose suggest the existence of a cross-talk mechanism between adipocytes and MCs that 
may be relevant in peritoneal membrane dysfunction developed during peritoneal dialysis.  
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6. Persistent release of proinflammatory mediators in patients under 
maintenance PD or after an episode of peritonitis 
Patients on maintenance PD have increased intra-peritoneal levels of hyaluronan and 
cytokines including IL-1, IL-6 and TGF- [33,34]. Chronic inflammation remains an 
important cause of morbidity in patients with end-stage renal failure. The main causes for 
inflammation in PD patients are PD-related peritonitis, continuous exposure to dialysis 
solutions and exit site infection [35]. Patients on PD with peritonitis may experience 
prolonged inflammation even when clinical evaluation suggests resolution of PD-related 
peritonitis [5]. The highly sensitive C-reactive protein remains significantly higher than 
baseline even by day 42 after an episode of peritonitis [36].  
A longitudinal study conducted in patients treated for PD-related peritonitis also revealed 
elevation of serum leptin levels during acute peritonitis. The rise was contributed to 
anorexia in the earlier stage. In contrast, the serum adiponectin levels fell showing an 
inverse correlation between these two adipokines during acute peritonitis. Furthermore, the 
protracted course of inflammation even after bacterial cure of peritonitis was likely to cause 
the loss of lean body mass and to increase mortality [36]. 
7. Clinical syndrome of chronic inflammation in PD 
The above-mentioned dialysis risk factors and certain PD-specific characteristics are 
associated with the inflammatory burden possibly linking inflammation, increased 
peritoneal solute transport rate and declined residual renal function to poor outcome. Both 
local (intra-peritoneal) and systemic inflammation may additively be the cause and 
consequence of peritoneal membrane failure, and are important prognosticators of mortality 
in PD patients. Several factors deserve special emphasis. It has been shown that even with 
apparent clinical remission of PD-related peritonitis, dialysis patients, after an episode of 
peritonitis, may still be affected by prolonged systemic chronic inflammation. The 
significantly prolonged inflammation contributed to a poorer nutritional status and higher 
mortality [36]. The finding is consistent with our previous study that the level of cytokines in 
the peritoneal effluent remained higher than that in non-infective effluent throughout the 6-
week post-peritonitis period in parallel with elevated serum C reactive protein (CRP), 
despite clinical remission [5]. One-sixth of these patients with prolonged elevation of serum 
CRP died of a cardiovascular event over a median period of 17 months [37]. Therefore, the 
prolonged inflammation is likely to potentiate atherogenesis and increase the risk of 
cardiovascular events.  
Other than persistent low-grade inflammation, subclinical malnutrition may be another 
factor for the high mortality in these patients. Chronic inflammation with atherosclerosis is 
closely related to malnutrition, forming the malnutrition–inflammation–atherosclerosis 
(MIA) syndrome [37]. The underlying mechanism for malnourishment is likely to be 
multifactorial. Possible contributory factors include protein loss in the dialysate, the feeling 
of fullness due to PDF in abdomen, uremia-associated cachexia caused by leptin signaling 
through the hypothalamic melanocortin receptor [38], and protein energy wasting. The 
complications of membrane failure and fluid overload further enhance a higher incidence of 
cardiovascular events. Our proposal of a hypothetical mechanism of chronic inflammation in 
PD is shown in Figure 1. 
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Fig. 1. Interactions between peritonitis-related and non-infective factors leading to chronic 
inflammation and increased morbidity in peritoneal dialysis patients  
8. Newer osmotic agents in PDFs 
Low-GDP PDFs clearly have an advantage over high GDP solutions [14,39]. But the 
continued presence of glucose remains a significant problem for the cells. Alternative 
hypertonic agents with additive that may prevent chronic inflammation will continue to be 
a subject of research.    
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9. Conclusion 
During long-term maintenance PD, the peritoneal biology changes with chronic exposure to 
dialysate. Meticulous attention for chronic inflammation should be practiced in peritoneal 
dialysis patients, especially following peritonitis. Adequate nutritional support and 
screening for persistent inflammation are warranted such that the vicious circle like 
malnutrition–inflammation–atherosclerosis syndrome can be abolished.  
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